TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00281905
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT04270071
Drug: Yangxin Shengmai
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yangxin Shengmai Granules
Study: NCT04270071
Drug: Yangxin Shengmai placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yangxin Shengmai placebo have an identical appearance and scent as the active treatment granules.
Study: NCT04016779
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered once daily
Study: NCT02295020
Drug: Standard treatment only
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment such as NSAIDs and injections
Study: NCT01511874
Drug: ELIGARD 22.5mg
Normalized name: Eligard 22.5mg Suspension for Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: a subcutaneous injection of ELIGARD 22.5mg at 0 and 12weeks
Study: NCT01281202
Drug: Matching Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets
Study: NCT03015610
Drug: matched placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: these participants will receive a one-time dose of lansoprazole followed by PK analysis and then once daily placebo for 24 weeks
Study: NCT00978081
Drug: aminolevulinic acid hydrochloride
Normalized name: Aminolevulinic Acid Hydrochloride
DrugBank: Aminolevulinic acid (DB00855)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients undergo continuous or fractionated photodynamic therapy.
Study: NCT01883817
Drug: DHA Omega-3
Normalized name: MegaRed Kids Hello DHA Omega-3 Gummies (Watermelon and Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive a fixed dose of DHA (1,200 mg/day, 600 mg twice daily) or placebo (corn/soy oil) over 10 weeks
Study: NCT03813784
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1000 mg/m\^2 administered as continuous oral twice daily (BID) of each 3-week cycle.
Study: NCT01855243
Drug: regular insulin
Normalized name: Regular insulin
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01855243
Drug: 70/30 insulin
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02905981
Drug: Shohl's solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shohl's solution will be supplied as 500-milliliter (mL) bottles containing citric acid United States Pharmacopeia (USP) 640 milligrams per 5 milliliters (mg/5 mL) and hydrous sodium citrate USP 490 mg/5 mL. It will be administered during all Periods at a dose of 0.67 mmol/kg body weight.
Study: NCT02587598
Drug: I-DAC (Intermediate dose cytarabine)
Normalized name: Zodryl DAC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytarabine dose will be 1 g/m\^2. Cytarabine will be administered as an intravenous (IV) infusion.
Study: NCT01498432
Drug: Heliox21
Approvals — FDA: no, EMA: no, PMDA: no
Description: For Heliox21 the percentage of O2 will match the percentage of O2 prior to extubation, and Helium will make up the remainder (e.g. Helium 65% + O2 35%), and the O2 concentration will be titrated as their clinical condition indicates (as O2 increases Helium will decrease and vice versa).
Study: NCT00004465
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00423384
Drug: Ibandronate
Normalized name: ibandronate
DrugBank: Ibandronate (DB00710)
Approvals — FDA: no, EMA: no, PMDA: no
Description: I.v.
Study: NCT03613649
Drug: AZD0914
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spiropyrimidinetrione antibacterial drug, which inhibits bacterial DNA synthesis by a novel mechanism. Powder will be reconstituted in 60 mL of tap water and dosed orally after an overnight fast. After the cup containing 60 mL of zoliflodacin is taken, approximately 60 mL of tap water will be added to the cup and consumed by the subject to chase the initial dose.
Study: NCT02865720
Drug: CINRYZE 500 U
Normalized name: Cinryze 500 UNT Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion administered twice weekly
Study: NCT03044964
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be started on 500mg twice daily and may be increased to 1000mg twice daily after 1 week. Patients will or may remain on the 1000mg for 5 weeks.
Study: NCT02044991
Drug: Corticosteroid
Normalized name: CORTICOSTEROIDS
DrugBank: Corticosterone (DB04652)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40mg of a non-fluorinated injectable glucocorticoid, methylprednisolone acetate (1cc) combined with 1cc of 1% Lidocaine
Study: NCT02044991
Drug: Placebo Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: A placebo injection
Study: NCT03661138
Drug: Topical Corticosteroids (TCS)
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: It is administered concomitantly with upadacitinib or placebo.
Study: NCT02342886
Drug: HR (rifampicin plus isoniazid combination tablets)
Normalized name: Synovex H
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral
Study: NCT01426971
Drug: IBUPROFEN + CAFFEINE
Normalized name: caffeine / ergotamine / ibuprofen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: capsule Route of administration: oral
Study: NCT01426971
Drug: IBUPROFEN
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pharmaceutical form: capsule Route of administration: oral
Study: NCT01148303
Drug: Etoricoxib
Normalized name: etoricoxib
DrugBank: Etoricoxib (DB01628)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will take etoricoxib 90mg by mouth just before the start of the daily fast. This will be for six days. After this they will receive placebo for eight days.
Study: NCT01148303
Drug: Etoricoxib
Normalized name: etoricoxib
DrugBank: Etoricoxib (DB01628)
Approvals — FDA: no, EMA: no, PMDA: no
Description: This arm will receive placebo just before their fast for eight days. After this they will receive etoricoxib 90mg just before their daily fast for the next six days.
Study: NCT01148303
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT02064842
Drug: TMC435
Approvals — FDA: no, EMA: no, PMDA: no
Description: TMC435 1 capsule of 75 mg, 100 mg, and 150 mg taken orally on Days 1 to 7 in Part 2
Study: NCT02064842
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsule once daily taken orally on Day 1 in Part 1
Study: NCT02594904
Drug: Yinzhihuang Oral Liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: All the four groups will be given same treatment as being described in arm description.
Study: NCT04631484
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 ml of 0.9% sodium chloride (2 ampoules of 10 ml each), added to 200 ml of 0.9% sodium chloride, intravenously 2 times a day with an interval of 12 ± 2 hours, for 10 days
Study: NCT03361969
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo tablets
Study: NCT00856869
Drug: NRL972
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single 2 mg intravenous injection administered once after an overnight fast and once after a standard meal
Study: NCT01880086
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo pill that will have appearance identical to the treatment pill but will not contain active medication.
Study: NCT01512446
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 pill per week
Study: NCT03403348
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive matching placebo to JNJ-64417184 in Parts 1, 2A, 2B, 3, 4, 5 and 6.
Study: NCT01685138
Drug: LDK378
Approvals — FDA: no, EMA: no, PMDA: no
Description: LDK378/Ceritinib was supplied as 150 mg hard gelatin capsules and administered orally
Study: NCT02168530
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching placebo administered daily orally
Study: NCT01961895
Drug: Intravenous patient-controlled analgesia
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01155752
Drug: Pulmozyme single use ampule
Approvals — FDA: no, EMA: no, PMDA: no
Description: • Each Pulmozyme single use ampule delivers 2.5 mL (2.5 mg) of the sterile solution to the nebulizer bowl. The aqueous solution contains 1.0 mg/mL dornase alfa, 0.15 mg/mL calcium chloride dihydrate, and 8.77 mg/mL sodium chloride.
Study: NCT01155752
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: identical placebo
Study: NCT00774553
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose titration of oral suspension to a tolerable dose given twice daily for 10 days.
Study: NCT04231877
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT04231877
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT02768454
Drug: medical review of controlled broad-spectrum antibiotics
Normalized name: chlorhexidine gluconate Medicated Liquid Soap [Spectrum-4]
Approvals — FDA: no, EMA: no, PMDA: no
Description: medical review of outcome of antibiotics stewardship by pharmacists and infectious disease physicians
Study: NCT00603577
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xaliproden matching placebo. 1 capsule per day for 6 months or until resolution of PSN (whichever comes first).
Study: NCT00750139
Drug: NAFT-500
Approvals — FDA: no, EMA: no, PMDA: no
Description: topical cream 1 application every day up to 4 weeks weeks
Study: NCT00750139
Drug: Naftin 1%
Normalized name: Naftin 1% Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: topical allylamine cream applied once a day for up to 4 weeks
Study: NCT00896181
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT03571737
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen tablet
Study: NCT01454154
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as specified in the Treatment Arm.
Study: NCT01992653
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide will be administered at 750 milligrams per square meter (mg/m\^2) IV every 3 weeks (starting from Cycle 1 Day 1), for 6 or 8 cycles.
Study: NCT01992653
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxorubicin will be administered at 50 mg/m\^2 IV every 3 weeks (starting from Cycle 1 Day 1), for 6 or 8 cycles.
Study: NCT01992653
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisolone will be administered at 100 mg orally daily for 5 days every 3 weeks (starting from Cycle 1 Day 1), for 6 or 8 cycles. Prednisone at 100 mg orally from Day -7 to Day -1 may be given at the discretion of the treating investigator physician.
Study: NCT05982483
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Analgesia as dictated by the treating emergency physician
Study: NCT03724877
Drug: Long-acting beta2-agonist-long-acting muscarinic antagonists-inhaled corticosteroids(LABA-LAMA-ICS)
Approvals — FDA: no, EMA: no, PMDA: no
Description: (LABA-LAMA-ICS)
Study: NCT03724877
Drug: Long-acting beta2-agonist-inhaled corticosteroids-long-acting muscarinic antagonists (LABA-LAMA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: (LABA-LAMA)
Study: NCT02591095
Drug: ABT-263
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02269228
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03919851
Drug: Antibiotics
Normalized name: Antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of antibiotics
Study: NCT01258062
Drug: GelVac™ nasal powder H5N1 influenza vaccine.
Approvals — FDA: no, EMA: no, PMDA: no
Description: subjects will be randomized to either 30 µg of Inactivated H5N1 Influenza Vaccine Administered in GelVac™ Nasal Powder given as two doses of 15 μg in one nostril or placebo vaccine given as two doses administered in GelVac™ Nasal Powder in one nostril
Study: NCT01258062
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: subjects will be randomized to either 30 µg of Inactivated H5N1 Influenza Vaccine Administered in GelVac™ Nasal Powder given as two doses of 15 μg in one nostril or placebo vaccine given as two doses administered in GelVac™ Nasal Powder in one nostril
Study: NCT00760695
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablets, twice daily, for 4 weeks
Study: NCT03971539
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo film-coated tablet matching BI 894416.
Study: NCT03733574
Drug: LY03005
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: LY03005 80 mg, oral tablets, single dose
Study: NCT01340027
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT00142727
Drug: Full opioid agonist
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00142727
Drug: Opioid antagonist
Normalized name: OPIOID ANTAGONIST ANALGESICS
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03343197
Drug: AG-120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prior to surgery subjects will receive AG-120 administered continuously as a single agent dosed orally on Days 1 to 28 of a 28-day cycle. Subjects without residual disease following surgery will have the option to receive treatment for up to a year, until disease progression or unacceptable toxicity, whichever occurs first. Subjects with residual disease following surgery will have the option to receive treatment, until disease progression or unacceptable toxicity.
Study: NCT03343197
Drug: AG881
Normalized name: Agenebrutinib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prior to surgery subjects will receive AG-881 administered continuously as a single agent dosed orally on Days 1 to 28 of a 28-day cycle. Subjects without residual disease following surgery will have the option to receive treatment for up to a year, until disease progression or unacceptable toxicity, whichever occurs first. Subjects with residual disease following surgery will have the option to receive treatment, until disease progression or unacceptable toxicity.
Study: NCT02330367
Drug: AC0010
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phase 1: AC0010 will be administered in escalating dosages in a period of 28-day cycles.~Phase 2: AC0010 will be administered twice-daily at RP2D.
Study: NCT00621868
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral
Study: NCT01986127
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: single intralesional administration during endoscopy
Study: NCT02161237
Drug: Advagraf®
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT01702480
Drug: GSK2981710
Approvals — FDA: no, EMA: no, PMDA: no
Description: Will be available as 10 g medium-chain triglycerides (MCT) powder sachet that will be mixed with 125 - 250 milliliters (ml) water in a shaker and taken within 15 minutes of completion of breakfast
Study: NCT01702480
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Will be available as matching powder that will be mixed with 125 - 250 milliliters (ml) water in a shaker and taken within 15 minutes of completion of breakfast
Study: NCT01938430
Drug: LDV/SOF
Approvals — FDA: no, EMA: no, PMDA: no
Description: LDV/SOF FDC tablet administered orally once daily
Study: NCT00535782
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to tocilizumab administered by intravenous infusion every 4 weeks.
Study: NCT00535782
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered orally or parenterally, 7.5-25 mg weekly.
Study: NCT03888807
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo is the Biofreeze product with all active ingredients removed. The product will be applied immediately after walking. The participant will wait 15 minutes prior to walking again.
Study: NCT01840085
Drug: 0.03% DSC127 topical gel
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00925548
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 300 mg/m\^2 (to a maximum of 600 mg) of intravenous cyclophosphamide.
Study: NCT03390387
Drug: Standard induction therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (6 mg/m2, p/o; 1-29 days); Daunorubicin (45 mg/m2, i.v.; day 8 and 22); Vincristine (1.5 mg/m2, i.v.; days 8, 15, 22, 29 and 36); Triple intrathecal therapy (Methotrexate/Cytarabine/Prednisone; days 0/1, 8, 15, 22, 29 and 36)
Study: NCT02680548
Drug: 0.9% saline
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01619007
Drug: Standard of care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients who will be treated for an acute deep vein thrombosis (DVT) with current standard of care comprising e.g. of initial treatment with low-molecular weight heparin or fondaparinux, followed by oral Vitamin-K antagonist for at least 3 months
Study: NCT04080843
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine is a capsule in the form of 500 mg, orally, 850 mg/m2, twice daily, 2 weeks on/1 week off.
Study: NCT01298505
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo given twice daily for 7 days
Study: NCT04462666
Drug: Huzhang granule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empty the content of one sachet into a mug, add 50ml warm water, stir until dissolved, add another 50ml hot water. Consume and complete all 100ml liquid mixture as a single dosage.
Study: NCT04462666
Drug: Etoricoxib
Normalized name: etoricoxib
DrugBank: Etoricoxib (DB01628)
Approvals — FDA: no, EMA: no, PMDA: no
Description: take one capsule per day in the morning, at approximately 30 minutes after the meal.
Study: NCT04462666
Drug: Huzhang granule Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empty the content of one sachet into a mug, add 50ml warm water, stir until dissolved, add another 50ml hot water. Consume and complete all 100ml liquid mixture as a single dosage.
Study: NCT04462666
Drug: Etoricoxib Placebo
Normalized name: etoricoxib
DrugBank: Etoricoxib (DB01628)
Approvals — FDA: no, EMA: no, PMDA: no
Description: take one capsule per day in the morning, at approximately 30 minutes after the meal.
Study: NCT04482543
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intra-silicone oil injection of 250 µg methotrexate is done at the end of surgery and is repeated at weeks 3 and 6 postoperatively.
Study: NCT02621957
Drug: Pravastatin
Normalized name: Pravastatin
DrugBank: Pravastatin (DB00175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will receive a single oral dose of 10 mg pravastatin on Day 1 in Period 1 and Day 7 in Period 2.
Study: NCT04093115
Drug: CX1106
Approvals — FDA: no, EMA: no, PMDA: no
Description: administration of CX1106 at 740 mg/m2 as a 24-hour continuous infusion for 5 days (120 h, d1-5), 21 days per cycle, no more than 6 cycles
Study: NCT00731692
Drug: FTY720
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fingolimod capsules at doses of 1.25 mg (prior to implementation of Amendment 5) and 0.5 mg (after Amendment 5) were administered orally once daily
Study: NCT00731692
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo capsules were administered orally once daily
Study: NCT03306329
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets administered once daily
Study: NCT01858649
Drug: 5 FU
Normalized name: i5 Functional Food Nutritional Powder for Suspension (Vanilla Delight)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leucovorin L (levoleucovorin) 200 mg/m2 (or folinic acid 400 mg/m²) in 250 ml glucose 5%, IV infusion 3 to 6 cycles 5-FU bolus 400 mg/m2, IV bolus 3 to 6 cycles 5-FU continuous infusion 2400 mg/m2, 46-hour cont. IV infusion 3 to 6 cycles
Study: NCT01439854
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients are treated with placebo
Study: NCT00116844
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT04561557
Drug: Cyclophosphamide and fludarabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive one 3-day cycle of lymphodepletion starting 4 days prior to CT103A infusion on Day 0.~Subjects will be given IV infusion of cyclophosphamide 300 mg/m2/day on day -4, -3 and -2, and fludarabine 30 mg/m2 over 30 minutes administered immediately after cyclophosphamide.
Study: NCT00879346
Drug: AZD8931
Approvals — FDA: no, EMA: no, PMDA: no
Description: 160mg oral single dose (4 x 40mg tablets)
Study: NCT02073461
Drug: CD1579 2.5%
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04180137
Drug: Pharmacotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: After surgical intervention the active treatment group will receive sulodexide 250 lipasemic units (LSU) bid for 30 days.
Study: NCT02073461
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02013310
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05121714
Drug: Caffeine
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: This is a 2 part, fixed-sequence open-label, crossover study to evaluate the potential CYP1A2-mediated drug-drug interactions (DDI), safety, and tolerability of ABX464 combined with a known CYP1A2 substrate (caffeine)
Study: NCT04023071
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Conditioning agent
Study: NCT04726657
Drug: Premixed Human Isophane Insulin Suspension + Human Insulin Injection
Normalized name: insulin isophane, human
Approvals — FDA: no, EMA: no, PMDA: no
Description: premixed human insulin
Study: NCT02387606
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive placebo once daily.
Study: NCT00701259
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01767688
Drug: MK-3102
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of 25 mg of MK-3102 (1 x 25 mg capsule) administered orally on Day 1.
Study: NCT00766675
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen oral tablet will be administered at a dose of 325 milligram as, once daily for Day 1-3, twice daily for Day 4-6 and thrice daily for Day 7-56.